Bolt Biotherapeutics, Inc. (BOLT)
6.27
+2.08
(+49.64%)
USD |
NASDAQ |
Oct 23, 16:00
6.85
+0.58
(+9.25%)
After-Hours: 20:00
Bolt Biotherapeutics Enterprise Value : 15.90M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 15.90M |
| October 22, 2026 | 11.90M |
| October 21, 2026 | 11.80M |
| October 20, 2026 | 12.13M |
| October 19, 2026 | 11.61M |
| October 16, 2026 | 11.53M |
| October 15, 2026 | 11.99M |
| October 14, 2026 | 11.49M |
| October 13, 2026 | 12.08M |
| October 12, 2026 | 11.99M |
| October 09, 2026 | 11.74M |
| October 08, 2026 | 10.86M |
| October 07, 2026 | 10.76M |
| October 06, 2026 | 10.59M |
| October 05, 2026 | 10.57M |
| October 02, 2026 | 10.47M |
| October 01, 2026 | 10.59M |
| September 30, 2026 | 10.91M |
| September 29, 2026 | 10.76M |
| September 28, 2026 | 10.49M |
| September 25, 2026 | 10.72M |
| September 24, 2026 | 10.74M |
| September 23, 2026 | 10.86M |
| September 22, 2026 | 10.97M |
| September 21, 2026 | 10.74M |
| Date | Value |
|---|---|
| September 18, 2026 | 10.68M |
| September 17, 2026 | 10.27M |
| September 16, 2026 | 10.82M |
| September 15, 2026 | 11.59M |
| September 14, 2026 | 11.49M |
| September 11, 2026 | 11.43M |
| September 10, 2026 | 11.01M |
| September 09, 2026 | 10.91M |
| September 08, 2026 | 11.26M |
| September 04, 2026 | 11.34M |
| September 03, 2026 | 11.33M |
| September 02, 2026 | 11.22M |
| September 01, 2026 | 11.67M |
| August 31, 2026 | 11.49M |
| August 28, 2026 | 11.17M |
| August 27, 2026 | 11.53M |
| August 26, 2026 | 11.38M |
| August 25, 2026 | 11.24M |
| August 24, 2026 | 11.03M |
| August 21, 2026 | 10.89M |
| August 20, 2026 | 9.990M |
| August 19, 2026 | 10.11M |
| August 18, 2026 | 9.947M |
| August 17, 2026 | 9.990M |
| August 14, 2026 | 10.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.72M |
| Revenue (Quarterly) | 0.005M |
| Total Expenses (Quarterly) | 7.725M |
| EPS Diluted (Quarterly) | -4.567 |
| Gross Profit Margin (Quarterly) | -3.32K% |
| Profit Margin (Quarterly) | -154.4K% |
| Earnings Yield | -262.2% |
| Normalized Earnings Yield | -247.27 |